RU2007125644A - Отбор пациентов для терапии ингибитором her - Google Patents
Отбор пациентов для терапии ингибитором her Download PDFInfo
- Publication number
- RU2007125644A RU2007125644A RU2007125644/13A RU2007125644A RU2007125644A RU 2007125644 A RU2007125644 A RU 2007125644A RU 2007125644/13 A RU2007125644/13 A RU 2007125644/13A RU 2007125644 A RU2007125644 A RU 2007125644A RU 2007125644 A RU2007125644 A RU 2007125644A
- Authority
- RU
- Russia
- Prior art keywords
- her2
- patient
- sample
- tumor
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (41)
1. Способ лечения злокачественной опухоли, включающий введение пациенту ингибитора HER в количестве, эффективном для лечения злокачественной опухоли, где образец опухоли пациента экспрессирует два или более рецепторов HER и один или нескольких лигандов HER.
2. Способ по п.1, где рецепторы HER выбраны из группы, состоящей из EGFR, HER2 и HER3.
3. Способ по п.2, где рецепторы HER представляют собой EGFR и HER2.
4. Способ по п.2, где рецепторы HER представляют собой HER2 и HER3.
5. Способ по п.1, где лиганд HER выбран из группы, состоящей из бетацеллюлина, амфирегулина, эпирегулина и TGFα.
6. Способ по п.5, где лиганд HER представляет собой бетацеллюлин.
7. Способ по п.5, где лиганд HER представляет собой амфирегулин.
8. Способ по п.1, где образец опухоли экспрессирует HER2 и EGFR или HER3, а также бетацеллюлин или амфирегулин.
9. Способ по п.8, где образец опухоли экспрессирует HER2 и EGFR, а также бетацеллюлин.
10. Способ по п.1, где ингибитор HER представляет собой ингибитор димеризации HER.
11. Способ по п.1, где ингибитор HER представляет собой антитело к HER.
12. Способ по п.11, где антитело к HER представляет собой антитело к HER2.
13. Способ по п.12, где антитело к HER2 связывается с доменом II внеклеточного домена HER2.
14. Способ по п.13, где антитело к HER2 представляет собой пертузумаб.
15. Способ по любому из пп.11-14, где антитело к HER представляет собой свободное антитело.
16. Способ по любому из пп.11-14, где антитело к HER представляет собой интактное антитело.
17. Способ по любому из пп.11-14, где антитело к HER2 представляет собой фрагмент антитела, содержащий антигенсвязывающую область.
18. Способ по п.1, где экспрессию определяют посредством количественного анализа мРНК, кодирующей рецептор или лиганд HER.
19. Способ по п.18, где количество мРНК определяют с помощью полимеразной цепной реакции (ПЦР).
20. Способ по п.19, где ПЦР представляет собой количественную ПЦР с детекцией в реальном времени (кПЦР-РВ).
21. Способ по п.1, где образец опухоли представляет собой фиксированный образец опухоли.
22. Способ по п.21, где образец опухоли представляет собой фиксированный в формалине погруженный в парафин (FFPE) образец опухоли.
23. Способ по п.1, где образец опухоли представляет собой замороженный образец опухоли.
24. Способ по п.1, где экспрессия рецепторов HER и лиганда HER находится на среднем уровне или выше.
25. Способ по п.1, где злокачественная опухоль представляет собой рак яичников, перитонеальную злокачественную опухоль и злокачественную опухоль фаллопиевых труб.
26. Способ по п.1, где злокачественная опухоль представляет собой метастазирующий рак молочной железы (MBC).
27. Способ по п.1, где злокачественная опухоль представляет собой немелкоклеточный рак легких (NSCLC).
28. Способ по п.1, дополнительно включающий введение пациенту химиотерапевтического средства.
29. Способ по п.28, где химиотерапевтическое средство представляет собой антиметаболическое химиотерапевтическое средство.
30. Способ по п.29, где антиметаболическое химиотерапевтическое средство представляет собой гемцитабин.
31. Способ лечения злокачественной опухоли, включающий введение пациенту ингибитора HER в количестве, эффективном для лечения злокачественной опухоли, где образец опухоли пациента экспрессирует бетацеллюлин или амфирегулин.
32. Способ по п.31, где ингибитор HER ингибирует гетеродимеризацию HER2 с EGFR или HER3.
33. Способ лечения злокачественной опухоли, включающий введение пациенту антитела к HER2, связывающегося с доменом II HER2, в количестве, эффективном для лечения злокачественной опухоли, где образец опухоли пациента экспрессирует HER2 и EGFR или HER3, а также бетацеллюлин или амфирегулин.
34. Способ по п.33, где антитело HER2 связывается с местом соединения доменов I, II и III HER2.
35. Способ оценки фосфорилирования или активации HER в биологическом образце, включающий определение экспрессии двух или более рецепторов HER и одного или нескольких лигандов HER в образце, где экспрессия двух или более рецепторов HER и одного или нескольких лигандов HER служит признаком фосфорилирования или активации HER в образце.
36. Способ по п.35, где образец представляет собой погруженный в парафин, фиксированный в формалине образец опухоли.
37. Способ оценки фосфорилирования или активации HER в биологическом образце, включающий определение экспрессии бетацеллюлина или амфирегулина в образце, где экспрессия бетацеллюлина или амфирегулина служит признаком фосфорилирования или активации HER в образце.
38. Способ определения пациента для лечения ингибитором димеризации HER, включающий определение экспрессии двух или более рецепторов HER и одного или нескольких лигандов HER в образце пациента, где экспрессия рецепторов HER и лиганда HER служит признаком того, что пациент с большей вероятностью отвечает на лечение ингибитором димеризации HER.
39. Способ по п.38, где пациент представляет собой пациента со злокачественной опухолью.
40. Способ лечения рака яичников, включающий введение пациенту ингибитора HER в количестве, эффективном для лечения рака яичников, где образец опухоли пациента экспрессирует бетацеллюлин или амфирегулин.
41. Способ по п.40, где образец опухоли дополнительно экспрессирует два или более рецепторов HER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63394104P | 2004-12-07 | 2004-12-07 | |
US60/633,941 | 2004-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007125644A true RU2007125644A (ru) | 2009-01-20 |
Family
ID=36177671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007125644/13A RU2007125644A (ru) | 2004-12-07 | 2005-12-06 | Отбор пациентов для терапии ингибитором her |
Country Status (14)
Country | Link |
---|---|
US (2) | US20060121044A1 (ru) |
EP (1) | EP1825001A2 (ru) |
JP (1) | JP2008523073A (ru) |
KR (1) | KR20070085855A (ru) |
CN (1) | CN101115849A (ru) |
AR (1) | AR051524A1 (ru) |
AU (1) | AU2005314127A1 (ru) |
BR (1) | BRPI0518086A (ru) |
CA (1) | CA2587519A1 (ru) |
MX (1) | MX2007006529A (ru) |
NO (1) | NO20073487L (ru) |
RU (1) | RU2007125644A (ru) |
WO (1) | WO2006063042A2 (ru) |
ZA (1) | ZA200704796B (ru) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
PL217410B1 (pl) | 2000-05-19 | 2014-07-31 | Genentech Inc | Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
EP2163256B1 (en) | 2001-05-11 | 2015-09-02 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
KR20150043558A (ko) | 2004-07-22 | 2015-04-22 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
CN102580084B (zh) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
SI1850874T1 (sl) * | 2005-02-23 | 2014-01-31 | Genentech, Inc. | Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
EP1917528B1 (en) * | 2005-08-24 | 2011-08-17 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
JP2007135581A (ja) * | 2005-10-20 | 2007-06-07 | Japan Science & Technology Agency | 自己免疫性血小板減少性紫斑病(itp)患者の血液細胞特異的遺伝子群 |
BRPI0712077A2 (pt) * | 2006-05-01 | 2012-01-17 | Genentech Inc | prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa |
EP2097754B2 (en) * | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
US7825127B2 (en) * | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
CN101711284A (zh) * | 2007-01-25 | 2010-05-19 | 达娜-法勃肿瘤研究所 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
AU2008223069B2 (en) | 2007-03-02 | 2012-12-13 | F. Hoffmann-La Roche Ag | Predicting response to a HER dimerisation inhibitor based on low HER3 expression |
EP2171090B1 (en) * | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
WO2009026705A1 (en) * | 2007-08-24 | 2009-03-05 | The University Of Western Ontario | Method of diagnosing and treating osteoarthritis |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US9086414B2 (en) | 2008-07-08 | 2015-07-21 | George Mason Research Foundation, Inc. | Phosphorylated C-ErbB2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer |
EP2362783A2 (en) | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Light targeting molecules and uses thereof |
ES2594893T3 (es) * | 2009-12-16 | 2016-12-23 | Abbvie Biotherapeutics Inc. | Anticuerpos anti HER2 y sus usos |
EP2859893A1 (en) | 2010-03-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
CN103154035B (zh) | 2010-05-27 | 2017-05-10 | 根马布股份公司 | 针对her2的单克隆抗体 |
JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー/エス | Her2エピトープに対するモノクローナル抗体 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
ES2692379T3 (es) | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
US9828635B2 (en) * | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
SG10201606756PA (en) | 2011-10-14 | 2016-10-28 | Genentech Inc | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
CA2906175C (en) | 2013-03-15 | 2022-12-13 | Daniel J. Capon | Hybrid immunoglobulin containing non-peptidyl linkage |
CN105121471A (zh) | 2013-04-16 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 帕妥珠单抗变体及其评估 |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
LT3116486T (lt) | 2014-03-14 | 2020-04-10 | Biomolecular Holdings Llc | Hibridinis imunoglobulinas, turintis nepetidilinę jungtį |
AU2015249633B2 (en) | 2014-04-25 | 2020-10-15 | Genentech, Inc. | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab |
AU2016270686B2 (en) * | 2015-05-29 | 2019-12-19 | Expression Pathology, Inc. | Quantifying Her2 protein for optimal cancer therapy |
JP6822980B2 (ja) | 2015-05-30 | 2021-01-27 | ジェネンテック, インコーポレイテッド | Her2陽性転移性乳癌の治療方法 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
GB201611580D0 (en) * | 2016-07-01 | 2016-08-17 | Aslan Pharmaceuticals Pte Ltd | Method |
JP2019532999A (ja) | 2016-11-04 | 2019-11-14 | ジェネンテック, インコーポレイテッド | Her2陽性乳がんの治療 |
JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック, インコーポレイテッド | 進行したher2発現がんの治療 |
AU2018210312B2 (en) | 2017-01-17 | 2020-03-19 | F. Hoffmann-La Roche Ag | Subcutaneous HER2 antibody formulations |
EP3589661B1 (en) | 2017-03-02 | 2023-11-01 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
KR20190140952A (ko) | 2017-04-24 | 2019-12-20 | 제넨테크, 인크. | 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
AU675916B2 (en) * | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
DE69938923D1 (de) * | 1998-03-27 | 2008-07-31 | Genentech Inc | Synergie zwischen apo-2 ligand und antikörper gegen her-2 |
ATE370961T1 (de) * | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
US6573043B1 (en) * | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
SI1187632T1 (sl) * | 1999-05-14 | 2009-04-30 | Genentech Inc | Zdravljenje z anti-ErbB2 protitelesi |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) * | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
DE10084743T1 (de) * | 1999-06-25 | 2002-08-14 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern |
ES2282120T3 (es) * | 1999-06-25 | 2007-10-16 | Genentech, Inc. | Tratamiento del cancer de prostata con anticuerpos anti-erbb2. |
TR200200472T2 (tr) * | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
PL217410B1 (pl) * | 2000-05-19 | 2014-07-31 | Genentech Inc | Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
CA2490758C (en) * | 2002-07-15 | 2014-09-23 | Genentech, Inc. | Dosage form of recombinant humanized monoclonal antibody 2c4 |
US20040013297A1 (en) * | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
AU2003300504B2 (en) * | 2002-10-01 | 2009-10-01 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
WO2004046386A1 (en) * | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
WO2004048525A2 (en) * | 2002-11-21 | 2004-06-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
DK3170906T3 (en) * | 2003-06-24 | 2018-11-05 | Genomic Health Inc | PREDICTION OF THE LIKELI REVENUE OF CANCER |
AU2005232657B2 (en) * | 2004-04-08 | 2010-12-16 | David B. Agus | ErbB antagonists for pain therapy |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
KR20150043558A (ko) * | 2004-07-22 | 2015-04-22 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
CN102580084B (zh) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
SI1850874T1 (sl) * | 2005-02-23 | 2014-01-31 | Genentech, Inc. | Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba |
TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
BRPI0712077A2 (pt) * | 2006-05-01 | 2012-01-17 | Genentech Inc | prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa |
SI2056874T1 (sl) * | 2006-08-21 | 2012-12-31 | F. Hoffmann-La Roche Ag | Terapija tumorjev s protitelesom proti vegf |
-
2005
- 2005-12-06 CA CA002587519A patent/CA2587519A1/en not_active Abandoned
- 2005-12-06 US US11/295,229 patent/US20060121044A1/en not_active Abandoned
- 2005-12-06 JP JP2007545584A patent/JP2008523073A/ja active Pending
- 2005-12-06 MX MX2007006529A patent/MX2007006529A/es not_active Application Discontinuation
- 2005-12-06 EP EP05853228A patent/EP1825001A2/en not_active Withdrawn
- 2005-12-06 KR KR1020077012834A patent/KR20070085855A/ko not_active Application Discontinuation
- 2005-12-06 WO PCT/US2005/044247 patent/WO2006063042A2/en active Application Filing
- 2005-12-06 AU AU2005314127A patent/AU2005314127A1/en not_active Abandoned
- 2005-12-06 RU RU2007125644/13A patent/RU2007125644A/ru not_active Application Discontinuation
- 2005-12-06 ZA ZA200704796A patent/ZA200704796B/xx unknown
- 2005-12-06 BR BRPI0518086-4A patent/BRPI0518086A/pt not_active IP Right Cessation
- 2005-12-06 CN CNA2005800478629A patent/CN101115849A/zh active Pending
- 2005-12-07 AR ARP050105126A patent/AR051524A1/es not_active Application Discontinuation
-
2007
- 2007-07-05 NO NO20073487A patent/NO20073487L/no not_active Application Discontinuation
-
2008
- 2008-05-01 US US12/113,802 patent/US20080317753A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060121044A1 (en) | 2006-06-08 |
WO2006063042A2 (en) | 2006-06-15 |
ZA200704796B (en) | 2008-11-26 |
JP2008523073A (ja) | 2008-07-03 |
AU2005314127A1 (en) | 2006-06-15 |
US20080317753A1 (en) | 2008-12-25 |
EP1825001A2 (en) | 2007-08-29 |
KR20070085855A (ko) | 2007-08-27 |
MX2007006529A (es) | 2007-06-22 |
CN101115849A (zh) | 2008-01-30 |
CA2587519A1 (en) | 2006-06-15 |
NO20073487L (no) | 2007-09-05 |
WO2006063042A3 (en) | 2007-02-08 |
BRPI0518086A (pt) | 2008-10-28 |
AR051524A1 (es) | 2007-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007125644A (ru) | Отбор пациентов для терапии ингибитором her | |
JP2008523073A5 (ru) | ||
Nahta et al. | HER-2-targeted therapy: lessons learned and future directions | |
Yoon et al. | Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | |
Diermeier et al. | Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation | |
RU2404806C2 (ru) | Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her | |
CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
Davoli et al. | Progression and treatment of HER2-positive breast cancer | |
Guo et al. | L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival | |
RU2009115364A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
del Campo et al. | Update on novel therapeutic agents for cervical cancer | |
CY1113260T1 (el) | ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΚΑΡΚΙΝΟΥ ME TO ANTI-ErbB2 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟ ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟ ΜΟΝΟΚΛΩΝΙΚΟ ΑΝΤΙΣΩΜΑ 2C4 (rhuMab 2C4) | |
RU2013114360A (ru) | Биомаркеры и способы лечения | |
EP2260056A1 (en) | Combination therapy with c-met and her antagonists | |
CN105722997A (zh) | 癌症生物标记物及其应用 | |
Dancer et al. | Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization | |
JP2006508336A5 (ru) | ||
CA2739302A1 (en) | Treatment method | |
RU2010135585A (ru) | Моноклональные антитела для лечения опухолей | |
JP2008531576A5 (ru) | ||
JP2009536834A (ja) | 癌の診断及び治療のための方法及び組成物 | |
Oshima et al. | Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines | |
Ghedini et al. | Shed HER2 extracellular domain in HER2‐mediated tumor growth and in trastuzumab susceptibility | |
Thibault et al. | HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review | |
Kordes et al. | Targeted therapy for advanced esophagogastric adenocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100610 |